Patents by Inventor Irina Marianovsky

Irina Marianovsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090181894
    Abstract: The present invention relates particularly to neoplastic cells targeted chimeric toxins comprising of cell targeting moieties and cell killing moieties for recognizing and for destroying the neoplastic cells, wherein the cell targeting moieties consist of gonadotropin releasing hormone homologues and the cell killing moieties consist of Pseudomonas Exotoxin A. The present invention further relates to pharmaceutical compositions containing as an active ingredient these neoplastic cells targeted chimeric toxins and to a method for the production of these chimeric toxins. The said invention also relates to a method for cancer therapy, treating malignant carcinoma cells and benign hyperplasia including uterine leiomyoma cells, extrauterine endometrial island cells, benign hyperplasia of prostate and breast and pituitary tumor adenoma cells, by the use of the above-mentioned chimeric toxins.
    Type: Application
    Filed: March 13, 2009
    Publication date: July 16, 2009
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Shai Yarkoni, Amotz Nechushtan, Haya Lorberboum-Galski, Irina Marianovsky
  • Patent number: 6933271
    Abstract: The present invention relates particularly to neoplastic cells targeted chimeric toxins comprising of cell targeting moieties and cell killing moieties for recognizing and for destroying the neoplastic cells, wherein the cell targeting moieties consist of gonadotropin releasing hormone homologues and the cell killing moieties consist of Pseudomonas Exotoxin A. The present invention further relates to pharmaceutical compositions containing as an active ingredient these neoplastic cells targeted chimeric toxins and to a method for the production of these chimeric toxins. The said invention also relates to a method for cancer therapy, treating malignant carcinoma cells and benign hyperplasia including uterine lyomyoma cells, extra uterian endometrial island cells, benign hyperplasia of prostate and breast and pituitary tumor adenoma cells, by the use of the above-mentioned chimeric toxins.
    Type: Grant
    Filed: June 4, 1997
    Date of Patent: August 23, 2005
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Shai Yarkoni, Amotz Nechushtan, Haya Lorberboum-Galski, Irina Marianovsky
  • Patent number: 6531133
    Abstract: A chimeric protein comprising a Pseudomonas aeruginosa exotoxin (PE) moiety linked to a myelin basic protein (MBP) moiety is disclosed. The MBP moiety is selected from the group comprising: (a) MBP; (b) amino acids 69-88 of guinea-pig myelin basic protein or an antigenic portion thereof; (c) amino acids 84-102 of human myelin basic protein or an antigenic portion thereof; (d) amino acids 143-168 of human myelin basic protein or an antigenic portion thereof; and (e) an amino acid sequence in which one or more amino acids have been deleted, added, substituted or mutated in the amino acid sequences of (a), (b), (c) or (d), the modified sequence of (e) retaining at least 75% homology with the amino acid sequences of (a), (b), (c) or (d), respectively. Each of the MBP moieties of (b), (c) and (d) are linked to the PE moiety by a pentapeptide linker repeated 1-3 times. The chimeric protein is useful in treating autoimmune diseases, and especially multiple sclerosis.
    Type: Grant
    Filed: January 27, 1999
    Date of Patent: March 11, 2003
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Haya Lorberboum-Galski, Ida Steinberger, Eveline Beraud, Irina Marianovsky, Shai Yarkoni
  • Publication number: 20020028914
    Abstract: The present invention relates particularly to neoplastic cells targeted chimeric toxins comprising of cell targeting moieties and cell killing moieties for recognizing and for destroying the neoplastic cells, wherein the cell targeting moieties consist of gonadotropin releasing hormone homologues and the cell killing moieties consist of Pseudomonas Exotoxin A. The present invention further relates to pharmaceutical compositions containing as an active ingredient these neoplastic cells targeted chimeric toxins and to a method for the production of these chimeric toxins. The said invention also relates to a method for cancer therapy, treating malignant carcinoma cells and benign hyperplasia including uterine lyomyoma cells, extra uterian endometrial island cells, benign hyperplasia of prostate and breast and pituitary tumor adenoma cells, by the use of the above-mentioned chimeric toxins.
    Type: Application
    Filed: March 1, 1999
    Publication date: March 7, 2002
    Inventors: SHAI YARKONI, AMOTZ NECHUSHTAN, HAYA LORBERBOUM-GALSKI, IRINA MARIANOVSKY
  • Patent number: 6140066
    Abstract: The present invention relates to methods for cancer diagnosis using a chimeric toxin. In particular, the invention relates to the use of a chimeric toxin composed of gonadotropin releasing hormone (GnRH) and Pseudomonas exotoxin A (PE) to detect a tumor-associated epitope expressed by human adenocarcinomas. Mutated GnRH-PE molecules that bind but do not kill tumor cells are exemplified.
    Type: Grant
    Filed: March 24, 1998
    Date of Patent: October 31, 2000
    Inventors: Haya Lorberboum-Galski, Shai Yarkoni, Ahmi Ben-Yehudah, Irina Marianovsky, Amotz Nechushtan